Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Berg SL, et al. Among authors: lampkin ta. J Clin Oncol. 2005 May 20;23(15):3376-82. doi: 10.1200/JCO.2005.03.426. J Clin Oncol. 2005. PMID: 15908649 Clinical Trial.
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. Munster P, et al. Among authors: lampkin ta. Clin Cancer Res. 2016 Apr 15;22(8):1932-9. doi: 10.1158/1078-0432.CCR-15-1665. Epub 2015 Nov 24. Clin Cancer Res. 2016. PMID: 26603258 Clinical Trial.
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Olmos D, et al. Among authors: lampkin ta. Clin Cancer Res. 2011 May 15;17(10):3420-30. doi: 10.1158/1078-0432.CCR-10-2946. Epub 2011 Apr 1. Clin Cancer Res. 2011. PMID: 21459796 Clinical Trial.
Targeting Polo-like kinase in cancer therapy.
Degenhardt Y, Lampkin T. Degenhardt Y, et al. Clin Cancer Res. 2010 Jan 15;16(2):384-9. doi: 10.1158/1078-0432.CCR-09-1380. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068088 Review.
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D. Qian Y, et al. Among authors: lampkin ta. Clin Exp Metastasis. 2011 Dec;28(8):899-908. doi: 10.1007/s10585-011-9421-9. Epub 2011 Sep 21. Clin Exp Metastasis. 2011. PMID: 21953073 Free PMC article.